236 related articles for article (PubMed ID: 11562352)
1. Differential activities of the RET tyrosine kinase receptor isoforms during mammalian embryogenesis.
de Graaff E; Srinivas S; Kilkenny C; D'Agati V; Mankoo BS; Costantini F; Pachnis V
Genes Dev; 2001 Sep; 15(18):2433-44. PubMed ID: 11562352
[TBL] [Abstract][Full Text] [Related]
2. Phosphotyrosine 1062 is critical for the in vivo activity of the Ret9 receptor tyrosine kinase isoform.
Wong A; Bogni S; Kotka P; de Graaff E; D'Agati V; Costantini F; Pachnis V
Mol Cell Biol; 2005 Nov; 25(21):9661-73. PubMed ID: 16227613
[TBL] [Abstract][Full Text] [Related]
3. RET receptor tyrosine kinase isoforms in kidney function and disease.
Lee DC; Chan KW; Chan SY
Oncogene; 2002 Aug; 21(36):5582-92. PubMed ID: 12165857
[TBL] [Abstract][Full Text] [Related]
4. Distinct turnover of alternatively spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase.
Scott RP; Eketjäll S; Aineskog H; Ibáñez CF
J Biol Chem; 2005 Apr; 280(14):13442-9. PubMed ID: 15677445
[TBL] [Abstract][Full Text] [Related]
5. Conservation of RET proto-oncogene splicing variants and implications for RET isoform function.
Carter MT; Yome JL; Marcil MN; Martin CA; Vanhorne JB; Mulligan LM
Cytogenet Cell Genet; 2001; 95(3-4):169-76. PubMed ID: 12063395
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of RET receptor isoforms in the olfactory system.
Kaplinovsky T; Cunningham AM
Neuroscience; 2011 Feb; 175():49-65. PubMed ID: 21118713
[TBL] [Abstract][Full Text] [Related]
7. Critical and distinct roles for key RET tyrosine docking sites in renal development.
Jain S; Encinas M; Johnson EM; Milbrandt J
Genes Dev; 2006 Feb; 20(3):321-33. PubMed ID: 16452504
[TBL] [Abstract][Full Text] [Related]
8. Alternative splicing results in RET isoforms with distinct trafficking properties.
Richardson DS; Rodrigues DM; Hyndman BD; Crupi MJ; Nicolescu AC; Mulligan LM
Mol Biol Cell; 2012 Oct; 23(19):3838-50. PubMed ID: 22875993
[TBL] [Abstract][Full Text] [Related]
9. The long and short isoforms of Ret function as independent signaling complexes.
Tsui-Pierchala BA; Ahrens RC; Crowder RJ; Milbrandt J; Johnson EM
J Biol Chem; 2002 Sep; 277(37):34618-25. PubMed ID: 12091387
[TBL] [Abstract][Full Text] [Related]
10. Expression of RET 3' splicing variants during human kidney development.
Ivanchuk SM; Myers SM; Mulligan LM
Oncogene; 1998 Feb; 16(8):991-6. PubMed ID: 9519873
[TBL] [Abstract][Full Text] [Related]
11. Differential requirement of Tyr1062 multidocking site by RET isoforms to promote neural cell scattering and epithelial cell branching.
Degl'Innocenti D; Arighi E; Popsueva A; Sangregorio R; Alberti L; Rizzetti MG; Ferrario C; Sariola H; Pierotti MA; Borrello MG
Oncogene; 2004 Sep; 23(44):7297-309. PubMed ID: 15326489
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas.
Ramone T; Romei C; Ciampi R; Tacito A; Piaggi P; Torregrossa L; Ugolini C; Elisei R
Endocrine; 2019 Sep; 65(3):623-629. PubMed ID: 31278686
[TBL] [Abstract][Full Text] [Related]
13. C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET.
Reynolds L; Jones K; Winton DJ; Cranston A; Houghton C; Howard L; Ponder BA; Smith DP
Oncogene; 2001 Jul; 20(30):3986-94. PubMed ID: 11494127
[TBL] [Abstract][Full Text] [Related]
14. The neuronal scaffold protein Shank3 mediates signaling and biological function of the receptor tyrosine kinase Ret in epithelial cells.
Schuetz G; Rosário M; Grimm J; Boeckers TM; Gundelfinger ED; Birchmeier W
J Cell Biol; 2004 Dec; 167(5):945-52. PubMed ID: 15569713
[TBL] [Abstract][Full Text] [Related]
15. 5'-End RET splicing: absence of variants in normal tissues and intron retention in pheochromocytomas.
Le Hir H; Charlet-Berguerand N; de Franciscis V; Thermes C
Oncology; 2002; 63(1):84-91. PubMed ID: 12187076
[TBL] [Abstract][Full Text] [Related]
16. Relative expression of the RET9 and RET51 isoforms in human pheochromocytomas.
Le Hir H; Charlet-Berguerand N; Gimenez-Roqueplo A; Mannelli M; Plouin P; de Franciscis V; Thermes C
Oncology; 2000 May; 58(4):311-8. PubMed ID: 10838497
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.
Pasini A; Geneste O; Legrand P; Schlumberger M; Rossel M; Fournier L; Rudkin BB; Schuffenecker I; Lenoir GM; Billaud M
Oncogene; 1997 Jul; 15(4):393-402. PubMed ID: 9242375
[TBL] [Abstract][Full Text] [Related]
18. 3' Splicing variants of ret receptor tyrosine kinase are differentially expressed in mouse embryos and in adult mice.
Lee KY; Samy ET; Sham MH; Tam PK; Lui VC
Biochim Biophys Acta; 2003 May; 1627(1):26-38. PubMed ID: 12759189
[TBL] [Abstract][Full Text] [Related]
19. Differential roles of RET isoforms in medullary and papillary thyroid carcinomas.
Lian EY; Maritan SM; Cockburn JG; Kasaian K; Crupi MJ; Hurlbut D; Jones SJ; Wiseman SM; Mulligan LM
Endocr Relat Cancer; 2017 Jan; 24(1):53-69. PubMed ID: 27872141
[TBL] [Abstract][Full Text] [Related]
20. CD2-associated protein (CD2AP) enhances casitas B lineage lymphoma-3/c (Cbl-3/c)-mediated Ret isoform-specific ubiquitination and degradation via its amino-terminal Src homology 3 domains.
Calco GN; Stephens OR; Donahue LM; Tsui CC; Pierchala BA
J Biol Chem; 2014 Mar; 289(11):7307-19. PubMed ID: 24425877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
